WS #15034
Eli Lilly's oral weight-loss drug Foundayo demonstrated superior efficacy compared to oral semaglutide in 52-week trials, showing 1.5% greater weight loss and 0.3% greater A1C reduction. This positive clinical data provides a rare bright spot in the healthcare sector, offering a defensive growth narrative amidst the broader macroeconomic turbulence. Conversely, Pharming saw leadership instability with its CEO stepping down immediately.
Healthcare & Pharma Breakthroughs
Eli Lilly's oral weight-loss drug Foundayo demonstrated superior efficacy compared to oral semaglutide in 52-week trials, showing 1.5% greater weight loss and 0.3% greater A1C reduction. This positive clinical data provides a rare bright spot in the healthcare sector, offering a defensive growth narrative amidst the broader macroeconomic turbulence. Conversely, Pharming saw leadership instability with its CEO stepping down immediately.